Evaluation of ultrasound-guided fine-needle aspiration biopsy for thyroid nodules.

Second Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan.
The American Journal of Surgery (Impact Factor: 2.52). 02/1998; 175(2):133-6. DOI: 10.1016/S0002-9610(97)00274-2
Source: PubMed

ABSTRACT We retrospectively studied whether ultrasound-guided fine-needle aspiration biopsy (US-FNAB) showed improved sensitivity in patients with palpable thyroid nodules.
A total of 70 patients (72 lesions) with thyroid nodules underwent US-FNAB and 94 patients (94 lesions) underwent FNAB guided by manual palpation (standard FNAB). The diagnoses obtained by US-FNAB were compared with the surgical findings.
The sensitivity of US-FNAB for palpable thyroid nodules was 62% the specificity was 74% the accuracy was 68% the positive predictive value was 100%, the negative predictive value was 70% and the inadequate biopsy rate was 17%. In contrast, the sensitivity of standard FNAB was 45%, the specificity was 51%, the accuracy was 48% the positive predictive value was 96, the negative predictive value was 55, and the inadequate biopsy rate was 30%. The accuracy of US-FNAB was significantly higher than that of standard FNAB. For tumors < or = 2 cm in diameter, the sensitivity and accuracy of US-FNAB were both significantly higher than those of standard FNAB.
These findings suggest that US-FNAB can improve the preoperative diagnosis of thyroid cancer, especially in patients with tumors < or = 2 cm in diameter.

  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: The rate of unsatisfactory samples from ultrasound-guided fine-needle aspirations of thyroid nodules varies widely in the literature. We aimed to evaluate our thyroid ultrasound-guided fine-needle aspiration biopsy technique in the absence of on-site microscopic examination by a pathologist; determine factors that affect the adequacy rate, such as the number of needle passes and needle size; compare our results with the literature; and establish an optimal technique. MATERIALS AND METHODS: We performed a retrospective review of cytopathology reports from 252 consecutive thyroid ultrasound-guided fine-needle aspiration biopsies performed by a radiologist between 2005 and 2010 in our hospital's radiology department. Sample adequacy, the number of needle passes, and needle size were determined. There was an on-site cytologist who prepared slides immediately after fine-needle aspiration but no on-site microscopic assessment of sample adequacy to guide the number of needle passes that should be performed. Cytopathology biopsy reports were classified as either unsatisfactory or satisfactory samples for diagnosis; the latter consisted of benign, malignant, and undetermined diagnoses. RESULTS: Seventy-seven biopsies were performed with 1 needle pass, 124 with 2 needle passes, and 51 with 3 needle passes. The rates of unsatisfactory biopsies were 33.8%, 23.4% (odds ratio [OR] 0.599 [95% confidence interval {CI}, 0.319-1.123]; P = .110), and 13.7% (OR 0.312 [95% CI, 0.124-0.788]; P = .014), respectively. CONCLUSION: In a hospital in which there is no on-site pathologist, a 3-pass method increases the specimen satisfactory rate by 20% compared with 1 pass, achieves similar rates to the literature, and provides a basis for further improvement of our practice.
    Canadian Association of Radiologists Journal 08/2012; · 0.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: High-resolution ultrasonography detects asymptomatic small thyroid nodules. These so called thyroid incidentalomas have created a clinical dilemma about their proper management. Aim: To report the incidence, clinical features and management of thyroid nodules of less than 1 cm diameter,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: There has been considerable difference in the mode of the imaging procedure and approach for the workup and post-surgery surveillance of thyroid cancer. Determination of serum thyroglobulin is recommended in the follow-up for monitoring the patients with differentiated thyroid carcinoma. Herein, the precise clinical role of individual imaging modalities is discussed, including ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI) and scintigraphic procedures for the diagnosis of recurrent or metastatic thyroid cancer. Method: A review is presented of the scientific papers published in the literature between 1982 and 2007. Relevant articles for this review were identified by searching PubMed using the following search terms: thyroid cancer, ultrasound, computerized tomography, magnetic resonance imaging and scintigraphy. The papers were analyzed and categorized in tabular form by date, subject, author and the type of scientific paper (e.g., randomized controlled trial, meta-analysis, clinical cases and review articles). Conclusion: Sonographic features of malignancy include microcalcifications, solid mass, absence of halo and internal blood flow, and these are helpful to predict thyroid malignancy in a nodule. Ultrasound is used for guiding fine needle aspiration to improve the accuracy of cytological analysis. However, biopsy is often necessary for a definitive diagnosis. This modality is also useful for postoperative neck evaluation of patients with elevated serum thyroglobulin levels to search for local recurrence or regional lymph node metastasis, which are the most common sites of recurrence. Tumor extension to the neighboring musculature, trachea, larynx and retropharyngeal, parapharyngeal and retrotracheal nodes are better defined by other anatomical imaging methods, such as CT or MRI. Anatomical imaging procedures are highly sensitive but not specific for postoperative evaluation of these patients and have few implications for deciding on subsequent I-131 therapy in patients with differentiated thyroid carcinoma. In addition to radioiodine scan, which has been the cornerstone of managing patients with differentiated thyroid cancer, nuclear imaging (scintigraphy) with technetium-99m sestamibi and tetrofosmin have all been used for determination of recurrent or metastatic differentiated thyroid cancer. Meta-iodo-benzylguanidine labeled either with I-123 or with I-131, 99mTc sestamibi and tetrofosmin and In-111 labeled somatostatin receptor analogues have been used for determination of recurrent or metastatic disease of medullary thyroid cancer. Over the last decade, positron emission tomography using 18-F-fluorodeoxyglucose has emerged as a useful tool in detecting non-iodine avid dedifferentiated and/or poorly differentiated thyroid cancer and plays a principal role in such settings.
    Expert Opinion on Medical Diagnostics 05/2009; 3(3):237-249.